Edgewise Therapeutics (EWTX) Preferred Stock Liabilities (2020)
Edgewise Therapeutics has reported Preferred Stock Liabilities over the past 1 years, most recently at $160.2 million for Q4 2020.
- Quarterly results put Preferred Stock Liabilities at $160.2 million for Q4 2020, changed N/A from a year ago — trailing twelve months through Dec 2020 was $160.2 million (changed N/A YoY), and the annual figure for FY2020 was $160.2 million, changed.
- Preferred Stock Liabilities reached $160.2 million in Q4 2020 per EWTX's latest filing.
- Across five years, Preferred Stock Liabilities topped out at $160.2 million in Q4 2020 and bottomed at $160.2 million in Q4 2020.